Metraipolis › archive › dc_af84fdeca121

FACS-based dual fluorescence reporter assay demonstrates efficacy of antisense oligonucleotide therapy of novel PRPF3 intronic splice variant — Europe PMC PMID:42211691

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42211691
DOI: 10.1016/j.omtn.2026.102949
License (as archived): solo-consultazione
Archived: 2026-11-01T09:16:06.875Z
SHA-256 of the archived text: d3e3dfee36d33161feade8e9d32e1caab96ef7a47e7a64d3090d20787eb09b0a
Stable URL of this page: https://metraipolis.com/documento/dc_af84fdeca121

How to cite

FACS-based dual fluorescence reporter assay demonstrates efficacy of antisense oligonucleotide therapy of novel PRPF3 intronic splice variant — Europe PMC PMID:42211691 — Europe PMC (en), https://europepmc.org/article/MED/42211691 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_af84fdeca121 (Metraipolis archive dc_af84fdeca121, sha256 d3e3dfee36d33161feade8e9d32e1caab96ef7a47e7a64d3090d20787eb09b0a)

BibTeX

@misc{dcaf84fdeca121,
  title = {FACS-based dual fluorescence reporter assay demonstrates efficacy of antisense oligonucleotide therapy of novel PRPF3 intronic splice variant — Europe PMC PMID:42211691},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42211691},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_af84fdeca121; sha256 d3e3dfee36d33161feade8e9d32e1caab96ef7a47e7a64d3090d20787eb09b0a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42211691. Agents can read the archived copy with the MCP tool read_document.